JP6139511B2 - 磁性グラフェン様ナノ粒子あるいは黒鉛ナノまたは微小粒子、およびそれらの生産および使用方法 - Google Patents
磁性グラフェン様ナノ粒子あるいは黒鉛ナノまたは微小粒子、およびそれらの生産および使用方法 Download PDFInfo
- Publication number
- JP6139511B2 JP6139511B2 JP2014510397A JP2014510397A JP6139511B2 JP 6139511 B2 JP6139511 B2 JP 6139511B2 JP 2014510397 A JP2014510397 A JP 2014510397A JP 2014510397 A JP2014510397 A JP 2014510397A JP 6139511 B2 JP6139511 B2 JP 6139511B2
- Authority
- JP
- Japan
- Prior art keywords
- graphene
- magnetic
- magnetic composition
- carbon
- nanoplatelets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000005291 magnetic effect Effects 0.000 title claims description 238
- 238000000034 method Methods 0.000 title claims description 66
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000002105 nanoparticle Substances 0.000 title description 18
- 239000011881 graphite nanoparticle Substances 0.000 title description 3
- 239000011859 microparticle Substances 0.000 title description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 503
- 229910021389 graphene Inorganic materials 0.000 claims description 327
- 239000002064 nanoplatelet Substances 0.000 claims description 189
- 239000002074 nanoribbon Substances 0.000 claims description 150
- 239000000203 mixture Substances 0.000 claims description 111
- 229910002804 graphite Inorganic materials 0.000 claims description 103
- 239000010439 graphite Substances 0.000 claims description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 71
- 229910052799 carbon Inorganic materials 0.000 claims description 67
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 66
- 229910052748 manganese Inorganic materials 0.000 claims description 64
- 229910052751 metal Inorganic materials 0.000 claims description 51
- 239000002184 metal Substances 0.000 claims description 48
- 239000002048 multi walled nanotube Substances 0.000 claims description 48
- 239000002086 nanomaterial Substances 0.000 claims description 47
- ZWXOQTHCXRZUJP-UHFFFAOYSA-N manganese(2+);manganese(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Mn+2].[Mn+3].[Mn+3] ZWXOQTHCXRZUJP-UHFFFAOYSA-N 0.000 claims description 23
- 229910052742 iron Inorganic materials 0.000 claims description 21
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 14
- 230000003381 solubilizing effect Effects 0.000 claims description 11
- 239000012286 potassium permanganate Substances 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical group OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 235000010344 sodium nitrate Nutrition 0.000 claims description 3
- 239000004317 sodium nitrate Substances 0.000 claims description 3
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 claims description 2
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 claims description 2
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 claims 1
- 239000011572 manganese Substances 0.000 description 112
- 230000002829 reductive effect Effects 0.000 description 76
- 239000002872 contrast media Substances 0.000 description 72
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 57
- 239000000523 sample Substances 0.000 description 42
- 230000005298 paramagnetic effect Effects 0.000 description 40
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 39
- 150000002500 ions Chemical class 0.000 description 37
- 230000005415 magnetization Effects 0.000 description 33
- 238000001362 electron spin resonance spectrum Methods 0.000 description 29
- 230000003647 oxidation Effects 0.000 description 26
- 238000007254 oxidation reaction Methods 0.000 description 26
- 238000005259 measurement Methods 0.000 description 25
- 238000007667 floating Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 239000007787 solid Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 238000001237 Raman spectrum Methods 0.000 description 19
- 238000003917 TEM image Methods 0.000 description 17
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000005294 ferromagnetic effect Effects 0.000 description 13
- 239000002616 MRI contrast agent Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000012512 characterization method Methods 0.000 description 11
- 230000005307 ferromagnetism Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 229910052688 Gadolinium Inorganic materials 0.000 description 10
- 238000001069 Raman spectroscopy Methods 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 230000007547 defect Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 229910021645 metal ion Inorganic materials 0.000 description 10
- 150000002739 metals Chemical class 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000010453 quartz Substances 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 239000002717 carbon nanostructure Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000009616 inductively coupled plasma Methods 0.000 description 9
- 230000005414 paramagnetic center Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000006722 reduction reaction Methods 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000002071 nanotube Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- BENFPBJLMUIGGD-UHFFFAOYSA-I trisodium;2-[2-[carboxylatomethyl-[[3-hydroxy-2-methyl-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methylpyridin-4-yl]methyl]amino]acetate;manganese(2+) Chemical compound [H+].[H+].[H+].[Na+].[Na+].[Na+].[Mn+2].CC1=NC=C(COP([O-])([O-])=O)C(CN(CCN(CC([O-])=O)CC=2C(=C(C)N=CC=2COP([O-])([O-])=O)[O-])CC([O-])=O)=C1[O-] BENFPBJLMUIGGD-UHFFFAOYSA-I 0.000 description 7
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- -1 but not limited to Chemical class 0.000 description 6
- 239000013522 chelant Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229910003472 fullerene Inorganic materials 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 6
- 229910017604 nitric acid Inorganic materials 0.000 description 6
- 229920001992 poloxamer 407 Polymers 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 5
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229910052747 lanthanoid Inorganic materials 0.000 description 5
- 150000002602 lanthanoids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000002867 manganese chloride Nutrition 0.000 description 5
- 239000011565 manganese chloride Substances 0.000 description 5
- 229940099607 manganese chloride Drugs 0.000 description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000004627 transmission electron microscopy Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000005292 diamagnetic effect Effects 0.000 description 4
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000005389 magnetism Effects 0.000 description 4
- 229910044991 metal oxide Inorganic materials 0.000 description 4
- 150000004706 metal oxides Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000002109 single walled nanotube Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229910052723 transition metal Inorganic materials 0.000 description 4
- 150000003624 transition metals Chemical class 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910021398 atomic carbon Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000003575 carbonaceous material Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000619 electron energy-loss spectrum Methods 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000000685 Carr-Purcell-Meiboom-Gill pulse sequence Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 229910052779 Neodymium Inorganic materials 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000005290 antiferromagnetic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000004697 chelate complex Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000020930 dietary requirements Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000004993 emission spectroscopy Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 description 2
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002075 inversion recovery Methods 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002113 nanodiamond Substances 0.000 description 2
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- DRKHJSDSSUXYTE-UHFFFAOYSA-L oxidanium;2-[bis[2-[carboxylatomethyl-[2-(2-methoxyethylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [OH3+].[Gd+3].COCCNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NCCOC DRKHJSDSSUXYTE-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910001006 Constantan Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001636 atomic emission spectroscopy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229910021399 diatomic carbon Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- LBVWYGNGGJURHQ-UHFFFAOYSA-N dicarbon Chemical compound [C-]#[C+] LBVWYGNGGJURHQ-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005685 electric field effect Effects 0.000 description 1
- 238000005430 electron energy loss spectroscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229940096814 gadobenate dimeglumine Drugs 0.000 description 1
- 229960002059 gadoversetamide Drugs 0.000 description 1
- 239000007770 graphite material Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000024 high-resolution transmission electron micrograph Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- DALUDRGQOYMVLD-UHFFFAOYSA-N iron manganese Chemical compound [Mn].[Fe] DALUDRGQOYMVLD-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000010244 region-of-interest analysis Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- PNYYBUOBTVHFDN-UHFFFAOYSA-N sodium bismuthate Chemical compound [Na+].[O-][Bi](=O)=O PNYYBUOBTVHFDN-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
- A61K49/0095—Nanotubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/182—Graphene
- C01B32/184—Preparation
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/182—Graphene
- C01B32/184—Preparation
- C01B32/19—Preparation by exfoliation
- C01B32/192—Preparation by exfoliation starting from graphitic oxides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B2204/00—Structure or properties of graphene
- C01B2204/20—Graphene characterized by its properties
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/10—Particle morphology extending in one dimension, e.g. needle-like
- C01P2004/17—Nanostrips, nanoribbons or nanobelts, i.e. solid nanofibres with two significantly differing dimensions between 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/20—Particle morphology extending in two dimensions, e.g. plate-like
- C01P2004/24—Nanoplates, i.e. plate-like particles with a thickness from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/42—Magnetic properties
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Manufacturing & Machinery (AREA)
- Molecular Biology (AREA)
- Composite Materials (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Carbon And Carbon Compounds (AREA)
- Hard Magnetic Materials (AREA)
Description
本願は、その内容が、参照することによりその全体として本明細書に組み込まれる、2011年5月6日出願の米国仮出願第61/483309号に対する優先権を主張するものである。
以下の実施例は、本発明の例証として提示され、いかようにも本発明を限定することを目的としていない。
材料および方法
磁気的挙動の特性化:
結果および考察
新規のグラフェンナノプレートレット(GNP、1〜5ナノメートル(nm)の厚さおよび約50nmの直径を伴うグラフェン(黒鉛の1原子厚さのシート)の小さいスタック(1〜12層))(図1aおよび1b)が、マウスのMRIスキャンにおいてMRI造影剤として試験された。GNPは、単分散、水溶性であり、挿入され(2つのグラフェンシート間の空隙内の化学種の挿入)、微量のマンガン(GNPの中の0.1%w/w(w=重量)のマンガン、すなわち、100グラムのGNPにつき0.1グラムのマンガン)と協調した。GNPは、Mn−DPDP(Teslascan、臨床MnベースのCA、3Tでr1=2.8mM−1s−1)よりもほぼ16倍高く、Gd−DTPA(Magnevist、臨床GdベースのCA、3Tでr1=4.2mM−1s−1)よりも約10倍高い、r1=45mM−1s−1の緩和能を示した。3テスラ臨床スキャナを使用した、T1加重小動物MRIを使用したスキャン(図6)は、臨床投与量におけるMagnevistと比較して、約100倍優れたコントラスト強化を示した。
グラフェンナノプレートレット(GNP)
マクロファージのヒスタミン放出は、MRI CAに対する種々の有害反応に関連した重要な現象である(非特許文献55)。ヒスタミンが豊富な顆粒を含有する、いくつかの細胞型における常在細胞である、マスト細胞(肥満細胞および肥大細胞としても知られている)が、0〜250mmol/lに及ぶGNP MRI CA(Magnevistが対照として使用される)濃度を含有する、緩衝液中で培養される。ヒスタミン放出が、ヒスタミン解放化合物48/80によって引き起こされる放出の50%に近づく濃度である、I50が計算される。
正味プロトン緩和時間であるT1mおよびT2mが、以下によって求められる。
PMは、Mn+2および水(H2O)のモル総数に対するマンガン(Mn+2)のモル分率である。ここで使用されたMn+2の濃度は、1mMであった。
1.全てのSBMパラメータを浮動させる(図18)。
2.Qを2で固定し、残りのSBMパラメータを浮動させる(図19)。
3.Qを4で固定し、残りのSBMパラメータを浮動させる(図20)。
4.Qを6で固定し、残りのSBMパラメータを浮動させる(図21)。
5.Qを8で固定し、残りのSBMパラメータを浮動させる(図22)。
6.Qを8で固定し、Tmを固定し、残りのSBMパラメータを浮動させる(図23)。
Claims (35)
- グラフェンナノ構造に挿入された磁性金属を備える磁性組成物であって、前記磁性金属がMnを含む、磁性組成物。
- 約10mM−1s−1以上の緩和能r1を有する、請求項1に記載の磁性組成物。
- 約20mM−1s−1以上の緩和能r1を有する、請求項2に記載の磁性組成物。
- 約45mM−1s−1以上の緩和能r1を有する、請求項2に記載の磁性組成物。
- 前記グラフェンナノ構造は、約20nm以下の厚さを有する、請求項1に記載の磁性組成物。
- 前記グラフェンナノ構造は、炭素の2〜12原子層を備える、請求項5に記載の磁性組成物。
- 前記グラフェンナノ構造は、炭素の2原子層を備える、請求項6に記載の磁性組成物。
- 前記グラフェンナノ構造は、炭素ナノプレートレットおよび炭素ナノリボンから成る群より選択される、請求項5に記載の磁性組成物。
- 前記グラフェンナノ構造は、5〜100nmの範囲内の平均直径を有する、炭素ナノプレートレットである、請求項8に記載の磁性組成物。
- 前記炭素ナノプレートレットは、約20nmの平均直径を有する、請求項9に記載の磁性組成物。
- 前記炭素ナノプレートレットは、約50nmの平均直径を有する、請求項9に記載の磁性組成物。
- 前記グラフェンナノ構造は、1〜250nmの範囲内の平均幅、および200〜5000nmの範囲内の平均長を有する、炭素ナノリボンである、請求項5に記載の磁性組成物。
- 前記炭素ナノリボンは、約120nmの平均幅、および600〜2000nmの範囲内の平均長を有する、請求項12に記載の磁性組成物。
- 前記炭素ナノプレートレットは、酸化ナノプレートレットである、請求項8に記載の磁性組成物。
- 前記Mnは、Mn酸化物の中に存在する、請求項1に記載の磁性組成物。
- 前記Mn酸化物は、二価および/または三価Mnを含む、請求項15に記載の磁性組成物。
- 前記Mn酸化物は、ハウスマン鉱を含む、請求項16に記載の磁性組成物。
- 1ppb〜106ppmの範囲内の量でMnを含む、請求項1に記載の磁性組成物。
- 前記グラフェンナノ構造は、炭素ナノプレートレットであり、前記磁性組成物は、106〜107ppmの範囲内の量でMnを含む、請求項18に記載の磁性組成物。
- 前記磁性組成物は、約5×106ppmの量でMnを含む、請求項19に記載の磁性組成物。
- 前記グラフェンナノ構造は、炭素ナノリボンであり、前記磁性組成物は、102〜103ppmの範囲内の量でMnを含む、請求項18に記載の磁性組成物。
- 前記磁性組成物は、5×102ppmの量でMnを含む、請求項21に記載の磁性組成物。
- MnおよびFeの両方を含む、請求項1に記載の磁性組成物。
- 前記グラフェンナノ構造は、炭素ナノリボンである、請求項23に記載の磁性組成物。
- 前記グラフェンナノ構造に付着した水溶性化部分をさらに含む、請求項1に記載の磁性組成物。
- 前記水溶性化部分は、前記グラフェンナノ構造に共有結合している、請求項25に記載の磁性組成物。
- 前記水溶性化部分は、前記グラフェンナノ構造に付着した、マロン酸およびセリノールマロノジアミドから成る群より選択される、請求項25に記載の磁性組成物。
- (i)請求項1〜27のいずれか一項に記載の十分な量の磁性組成物と、(ii)1つ以上の生理学的に容認可能な担体または賦形剤とを含む、磁気共鳴映像法とともに使用するための組成物。
- グラフェンナノ構造に挿入された磁性金属を備える磁性組成物を生産する方法であって、前記磁性金属がMnを含み、
(a)硫酸H2SO4、硝酸ナトリウムNaNO3、MnCl2、および過マンガン酸カリウムKMnO4の混合物で黒鉛を処理することと、
(b)ステップ(a)で得られた生成物の懸濁液を超音波で分解し、それにより、前記磁性組成物を生産することと、
を含む、方法。 - (c)還元剤で前記磁性組成物を処理することをさらに含む、
請求項29に記載の方法。 - 前記還元剤は、ヒドラジン水和物である、請求項30に記載の方法。
- グラフェンナノ構造に挿入された磁性金属を備える磁性組成物を生産する方法であって、前記磁性金属がMnを含み、
(a)硫酸H2SO4、MnCl2、および過マンガン酸カリウムKMnO4で多層炭素ナノチューブを処理することを含む、
方法。 - 前記ステップ(a)は、
(a1)H2SO4の中で前記多層炭素ナノチューブを懸濁させることと、
(a2)KMnO4およびMnCl2を添加することと、
(a3)ステップ(a2)で得られた混合物を加熱することと、
を含む、方法によって実行される、
請求項32に記載の方法。 - ステップ(a3)で、前記混合物は、55〜70℃まで加熱される、請求項33に記載の方法。
- 前記磁性組成物を水溶性化することをさらに含む、請求項29〜34のいずれか一項に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483309P | 2011-05-06 | 2011-05-06 | |
| US61/483,309 | 2011-05-06 | ||
| PCT/US2012/036790 WO2012154677A1 (en) | 2011-05-06 | 2012-05-07 | Magnetic graphene-like nanoparticles or graphitic nano-or microparticles and method of production and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516206A JP2014516206A (ja) | 2014-07-07 |
| JP6139511B2 true JP6139511B2 (ja) | 2017-05-31 |
Family
ID=47139573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510397A Expired - Fee Related JP6139511B2 (ja) | 2011-05-06 | 2012-05-07 | 磁性グラフェン様ナノ粒子あるいは黒鉛ナノまたは微小粒子、およびそれらの生産および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9713650B2 (ja) |
| EP (1) | EP2704902B1 (ja) |
| JP (1) | JP6139511B2 (ja) |
| KR (1) | KR20140082595A (ja) |
| CN (1) | CN103826840B (ja) |
| CA (1) | CA2835262A1 (ja) |
| WO (1) | WO2012154677A1 (ja) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8179133B1 (en) | 2008-08-18 | 2012-05-15 | Hypres, Inc. | High linearity superconducting radio frequency magnetic field detector |
| US8970217B1 (en) | 2010-04-14 | 2015-03-03 | Hypres, Inc. | System and method for noise reduction in magnetic resonance imaging |
| GB201021112D0 (en) | 2010-12-13 | 2011-01-26 | Ntnu Technology Transfer As | Nanowires |
| WO2012154677A1 (en) | 2011-05-06 | 2012-11-15 | The Research Foundation Of State University Of New York | Magnetic graphene-like nanoparticles or graphitic nano-or microparticles and method of production and uses thereof |
| GB201200355D0 (en) * | 2012-01-10 | 2012-02-22 | Norwegian Univ Sci & Tech Ntnu | Nanowires |
| WO2013162660A2 (en) * | 2012-01-27 | 2013-10-31 | William Marsh Rice University | Synthesis of magnetic carbon nanoribbons and magnetic functionalized carbon nanoribbons |
| GB201211038D0 (en) | 2012-06-21 | 2012-08-01 | Norwegian Univ Sci & Tech Ntnu | Solar cells |
| ES2706124T3 (es) * | 2013-01-30 | 2019-03-27 | Estrada Alfredo Vega | Nanoestructuras de carbono para el refuerzo de un tejido ocular |
| GB201311101D0 (en) | 2013-06-21 | 2013-08-07 | Norwegian Univ Sci & Tech Ntnu | Semiconducting Films |
| US9833522B2 (en) * | 2013-12-23 | 2017-12-05 | The Research Foundation For The State University Of New York | Graphene-based contrast agents for photoacoustic and thermoacoustic tomography and method of use |
| GB2523154B (en) | 2014-02-14 | 2016-04-27 | Cambridge Entpr Ltd | Method of producing graphene |
| CN104072868B (zh) * | 2014-06-12 | 2017-02-15 | 宁波信远石墨有限公司 | 一种类石墨烯改性导热塑料及其制备方法 |
| JP6502818B2 (ja) * | 2014-09-30 | 2019-04-17 | 積水化学工業株式会社 | 薄片化黒鉛及び薄片化黒鉛分散液の製造方法、並びに薄片化黒鉛、薄片化黒鉛分散液、薄片化黒鉛−樹脂複合材料及び炭素材料 |
| ES2716611T3 (es) * | 2014-10-10 | 2019-06-13 | Toray Industries | Polvo de grafeno, pasta de electrodos para la batería de iones de litio y electrodos para la batería de iones de litio |
| KR102313691B1 (ko) * | 2015-04-24 | 2021-10-20 | 일진머티리얼즈 주식회사 | 그래핀 제조방법 |
| WO2016191519A1 (en) * | 2015-05-26 | 2016-12-01 | The Research Foundation For The State University Of New York | Carbon material delivery systems and methods |
| DK3323152T3 (da) | 2015-07-13 | 2021-12-20 | Crayonano As | Nanowire-/nanopyramideformede lysdioder og fotodetektorer |
| AU2016292850B2 (en) | 2015-07-13 | 2019-05-16 | Crayonano As | Nanowires or nanopyramids grown on graphitic substrate |
| KR102698244B1 (ko) | 2015-07-31 | 2024-08-22 | 크래요나노 에이에스 | 그라파이트 기판 상에 나노와이어 또는 나노피라미드를 성장시키는 방법 |
| WO2018023033A1 (en) | 2016-07-29 | 2018-02-01 | Western Michigan University Research Foundation | Magnetic nanoparticle-based gyroscopic sensor |
| GB201705755D0 (en) | 2017-04-10 | 2017-05-24 | Norwegian Univ Of Science And Tech (Ntnu) | Nanostructure |
| KR20190076107A (ko) * | 2017-12-22 | 2019-07-02 | 장상구 | 치매와 같은 신경계 질환의 조기 진단 및 예방을 위한 인체 내 중금속의 자성화 정도 측정 키트 및 이들 중금속 자성체 제거용 나노다이아몬드 복합체 제조 방법 |
| CN110911653B (zh) * | 2018-09-18 | 2021-10-15 | 天津理工大学 | 四氧化三锰/碳纳米管复合材料及其制备方法和应用 |
| JP7426191B2 (ja) * | 2018-09-27 | 2024-02-01 | 太陽誘電株式会社 | 軟磁性金属粒子を含む磁性基体及び当該磁性基体を含む電子部品 |
| CN109877342B (zh) * | 2019-03-26 | 2020-08-25 | 中国科学技术大学 | 一种非晶贵金属纳米片及其制备方法 |
| KR20220062625A (ko) * | 2019-09-17 | 2022-05-17 | 그래프마테크 에이비 | 그래핀 물질로 코팅된 철 기반 입자를 가지는 복합 분말 |
| GB201913701D0 (en) | 2019-09-23 | 2019-11-06 | Crayonano As | Composition of matter |
| CN115697900A (zh) * | 2020-05-08 | 2023-02-03 | C2Cnt有限责任公司 | 磁性碳纳米材料及其制备方法 |
| CN111744059A (zh) * | 2020-07-03 | 2020-10-09 | 华中科技大学同济医学院附属协和医院 | 一种可粘膜下注射的稳定性磁性材料制备方法 |
| US12329042B1 (en) * | 2021-01-26 | 2025-06-10 | The Research Foundation For The State University Of New York | Quantum devices and methods using entangled photons and phonons |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090114883A1 (en) * | 2005-10-12 | 2009-05-07 | California Institute Of Technology | Metal-filled nanostructures |
| JP2009517463A (ja) * | 2005-12-02 | 2009-04-30 | インダストリー−アカデミック コーペレイション ファウンデイション, ヨンセイ ユニバーシティ | 水溶性マンガン酸化物ナノ粒子を含むmri造影剤 |
| US20090053512A1 (en) | 2006-03-10 | 2009-02-26 | The Arizona Bd Of Reg On Behalf Of The Univ Of Az | Multifunctional polymer coated magnetic nanocomposite materials |
| US20080213189A1 (en) | 2006-10-17 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Multifunctional metal-graphite nanocrystals |
| EP2182799A4 (en) | 2007-07-27 | 2015-01-21 | Univ Leland Stanford Junior | SUPRAMOLECULAR FUNCTIONALIZATION OF GRAPHITE NANOPARTICLES FOR ACTIVE EXTRACTION |
| CN101327926A (zh) | 2008-07-17 | 2008-12-24 | 华东理工大学 | 低温可膨胀石墨的制备方法 |
| US9598785B2 (en) * | 2008-09-11 | 2017-03-21 | Ramot At Tel-Aviv University Ltd. | Nanostructures and process of preparing same |
| CN101433726A (zh) * | 2008-12-18 | 2009-05-20 | 复旦大学 | 一种基于碳纳米管的磁共振造影剂及制备方法 |
| CN101474406B (zh) * | 2008-12-19 | 2011-01-26 | 天津医科大学 | 单层氧化石墨与四氧化三铁复合材料及制备和应用 |
| CN101525436B (zh) | 2009-03-20 | 2011-05-25 | 西北师范大学 | 聚吡咯/Fe3O4/纳米石墨薄片复合材料及其制备 |
| CN101650977B (zh) | 2009-09-09 | 2012-04-25 | 湖南大学 | 纳米铁氧化物/石墨复合电磁波吸收材料及其制备方法 |
| CN102397563B (zh) | 2010-09-16 | 2013-12-25 | 同济大学 | 一种磁共振成像造影剂用石墨烯纳米载体的制备方法 |
| CN102068705B (zh) | 2011-01-04 | 2012-11-07 | 上海师范大学 | 一种碳纳米管/壳聚糖/磁性铁酸盐纳米粒子复合材料及其制备方法和应用 |
| WO2012154677A1 (en) | 2011-05-06 | 2012-11-15 | The Research Foundation Of State University Of New York | Magnetic graphene-like nanoparticles or graphitic nano-or microparticles and method of production and uses thereof |
-
2012
- 2012-05-07 WO PCT/US2012/036790 patent/WO2012154677A1/en not_active Ceased
- 2012-05-07 KR KR1020137031518A patent/KR20140082595A/ko not_active Ceased
- 2012-05-07 EP EP12781824.3A patent/EP2704902B1/en active Active
- 2012-05-07 CA CA2835262A patent/CA2835262A1/en not_active Abandoned
- 2012-05-07 JP JP2014510397A patent/JP6139511B2/ja not_active Expired - Fee Related
- 2012-05-07 CN CN201280033576.7A patent/CN103826840B/zh not_active Expired - Fee Related
- 2012-05-07 US US14/116,102 patent/US9713650B2/en active Active
-
2017
- 2017-07-07 US US15/644,172 patent/US10610607B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170312374A1 (en) | 2017-11-02 |
| EP2704902A4 (en) | 2015-05-20 |
| CN103826840B (zh) | 2017-04-19 |
| JP2014516206A (ja) | 2014-07-07 |
| US9713650B2 (en) | 2017-07-25 |
| CN103826840A (zh) | 2014-05-28 |
| EP2704902B1 (en) | 2020-03-25 |
| WO2012154677A1 (en) | 2012-11-15 |
| US20140161730A1 (en) | 2014-06-12 |
| KR20140082595A (ko) | 2014-07-02 |
| EP2704902A1 (en) | 2014-03-12 |
| US10610607B2 (en) | 2020-04-07 |
| CA2835262A1 (en) | 2012-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6139511B2 (ja) | 磁性グラフェン様ナノ粒子あるいは黒鉛ナノまたは微小粒子、およびそれらの生産および使用方法 | |
| Paratala et al. | Physicochemical characterization, and relaxometry studies of micro-graphite oxide, graphene nanoplatelets, and nanoribbons | |
| Huang et al. | Tunable T 1 and T 2 contrast abilities of manganese-engineered iron oxide nanoparticles through size control | |
| Zhang et al. | Surface impact on nanoparticle-based magnetic resonance imaging contrast agents | |
| Ni et al. | Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T 1 contrast ability | |
| Wang et al. | Paramagnetic properties of metal-free boron-doped graphene quantum dots and their application for safe magnetic resonance imaging | |
| Chen et al. | Gd-encapsulated carbonaceous dots with efficient renal clearance for magnetic resonance imaging | |
| Jin et al. | An ultrasmall and metabolizable PEGylated NaGdF 4: Dy nanoprobe for high-performance T 1/T 2-weighted MR and CT multimodal imaging | |
| Antwi‐Baah et al. | Metal‐based nanoparticle magnetic resonance imaging contrast agents: classifications, issues, and countermeasures toward their clinical translation | |
| Sitharaman et al. | Gadofullerenes and gadonanotubes: A new paradigm for high-performance magnetic resonance imaging contrast agent probes | |
| Sethi et al. | The gadonanotubes revisited: a new frontier in MRI contrast agent design | |
| Pour et al. | Carboxymethyl cellulose (CMC)-loaded Co-Cu doped manganese ferrite nanorods as a new dual-modal simultaneous contrast agent for magnetic resonance imaging and nanocarrier for drug delivery system | |
| Khatik et al. | “Magnus nano-bullets” as T1/T2 based dual-modal for in vitro and in vivo MRI visualization | |
| Meng et al. | Bismuth-and gadolinium-codoped carbon quantum dots with red/green dual emission for fluorescence/CT/T1-MRI mode imaging | |
| US20130177503A1 (en) | Shape-controlled magnetic nanoparticles as t1 contrast agents for magnetic resonance imaging | |
| Liu et al. | Development of PEGylated KMnF 3 nanoparticles as a T 1-weighted contrast agent: chemical synthesis, in vivo brain MR imaging, and accounting for high relaxivity | |
| Mohanta et al. | Influence of oxidation degree of graphene oxide on its nuclear relaxivity and contrast in MRI | |
| Usman et al. | A bimodal theranostic nanodelivery system based on [graphene oxide-chlorogenic acid-gadolinium/gold] nanoparticles | |
| Zanganeh et al. | Magnetic particle imaging (MPI) | |
| Veintemillas-Verdaguer et al. | Continuous production of inorganic magnetic nanocomposites for biomedical applications by laser pyrolysis | |
| Ghaderi et al. | Magnetic resonance imaging property of doxorubicin-loaded gadolinium/13X zeolite/folic acid nanocomposite | |
| Boncel et al. | Magnetic carbon nanostructures in medicine | |
| CN103043724A (zh) | 一种氧化石墨烯/MnFe2O4纳米杂化材料及其制备方法 | |
| Paul et al. | Synthesis, characterization and in-vitro studies of CNT/Gd2O3 hybrid structure | |
| El-Gendy | Core/shell magnetic nanoparticles for biomedical applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170403 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170427 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6139511 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |